Drug Trial Radar · NCT04055818
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jan 24, 2020
Primary completion
Oct 30, 2028
Study completion Jan 20, 2029
Sponsor
- Lead sponsor
- EpiDestiny, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Aug 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Conditions
- Sickle Cell Disease
Interventions
NicotinamideDrug
Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood HemoglobinTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Illinois at Chicago College of Medicine
Chicago, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.